AUS
NZ
UK
CA
USA
IND
Haleon PLC (LSE:HLN), the consumer healthcare company headquartered in Weybridge, Surrey, has announced the appointment of Alan Stewart and Nancy Avila as non-executive directors, effective September 1. Stewart, previously the Chief Financial Officer (CFO) at Tesco PLC and Marks & Spencer Group PLC, is currently serving as a non-executive director at Diageo PLC and Burberry Group PLC. Avila, who has held roles such as Chief Information & Technology Officer at McKesson Corp, also brings experience from her tenures at Johnson Controls Inc. and Abbott Laboratories Inc.
Company Background
Haleon PLC was spun out from GSK PLC in 2022 and is engaged in the research, development, manufacture, and sale of a wide range of consumer healthcare products. The company's global operations span North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its portfolio includes a variety of products across oral health, pain relief, respiratory health, digestive health, and vitamins, minerals, and supplements. Notable brands under Haleon’s umbrella include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, Parodontax, and Centrum.
Corporate Evolution
Previously known as DRVW 2022 plc, the company rebranded to Haleon plc in February 2022 following its separation from GSK. Incorporated in 2021, Haleon has established itself as a prominent player in the consumer healthcare sector, leveraging its extensive portfolio to address diverse consumer needs worldwide. The appointments of Stewart and Avila are expected to bring expertise to Haleon’s board, further strengthening its leadership team.
